Galvanize Therapeutics, a commercial-stage medical technology company specializing in pulsed electric field (PEF) therapies, has successfully raised $100 million in an oversubscribed Series C financing round.

The investment was led by Sofinnova Partners, with participation from Norwest Venture Partners, Elevage Medical Technologies, Ally Bridge Group, Perceptive Xontogeny Venture Fund, Janus Henderson Investors, Longaeva, and existing investors including Fidelity Management & Research Company, T. Rowe Price, Gilmartin Capital, Intuitive Surgical, and founding investor Apple Tree Partners.

The funds will be utilized to expand the company’s commercial presence and advance clinical and development activities related to its Aliya® PEF system for solid tumors and RheOx® therapy for chronic bronchitis. The innovative PEF platform employs non-thermal, short-duration, highly focused electrical pulses to destabilize cellular pathological processes, aiming to alter disease trajectories without the use of pharmaceuticals.

In conjunction with the financing, Doug Godshall, former CEO of Shockwave Medical and HeartWare International, has been appointed Chairman and CEO of Galvanize Therapeutics. Jonathan Waldstreicher assumes the role of President and Chief Strategy Officer. (PR Newswire)

Galvanize Therapeutics is headquartered in Redwood City, California, and is committed to transforming the treatment of cancer and chronic lung diseases through its novel PEF technologies.